AR and metastatic prostate carcinoma: Apalutamide is a selective androgen receptor inhibitor indicated for the treatment of hormone-sensitive and metastatic prostate cancer associated with castration or treatment to inhibit androgen secretion, or resistant to chemical castration with a high risk of metastatic progression (7).